The tolerance of partial loss of X-chromosome dosage compensation in the brain in our study raises the prospect for therapeutic reactivation of MeCP2 or other genes in Rett syndrome and other X-linked genetic disorders in females. The gene discussed is MECP2; the disease is atypical Rett syndrome.